Spero Therapeutics (SPRO) investor relations material

Executive summary

• Focus shifted to tebipenem HBr after ceasing SPR206 and SPR720 programs; business now highly dependent on tebipenem HBr and GSK collaboration.

• Tebipenem HBr NDA for cUTI, including pyelonephritis, is under FDA review with a PDUFA date of June 18, 2026.

• Pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy; NDA resubmitted to FDA.

• No revenue from product sales; operations funded by license/collaboration payments and government contracts.

• Cash runway is projected to last into 2028, supporting ongoing operations and portfolio expansion.

Financial highlights

• Net loss for Q1 2026 was $7.2 million, improved from $13.9 million in Q1 2025.

• Total revenues for Q1 2026 were $0.3 million, down from $5.9 million in Q1 2025, due to lower collaboration and grant revenue.

• Research and development expenses decreased to $2.9 million from $13.6 million year-over-year, reflecting reduced clinical activity.

• General and administrative expenses decreased to $4.9 million from $6.8 million year-over-year.

• Cash and cash equivalents stood at $56.1 million as of March 31, 2026.

Outlook and guidance

• Cash and cash equivalents expected to fund operations at least into 2028 under current plans.

• Awaiting FDA decision on tebipenem HBr, with potential for milestone payments if approved.

• Additional funding will be needed beyond this period or if operating plans change.

• Focus remains on supporting GSK in FDA approval process and exploring new clinical-stage product opportunities.